Takeda Play

Filtrer videoene per terapiområde

Sikkerhet

The ADZYNMA safety profile was demonstrated in a Phase 3, open-label, crossover trial (NCT03393975), adverse events occurred in 71% of the patients with ADZYNMA.

Mer
Subscribe to